A look at what three ex-Genentech employees have accomplished at Denali so far.
This opinion piece presents the opinions of the author. It does not necessarily reflect the views of BioSpace.
I mentioned in the introduction the relative dearth of neuroscience investment, something we can hope will soon change. Denali Therapeutics is certainly one big sign of hope. The company, started by three ex-Genentech employees, is focused on neurodegenerative diseases like Parkinson’s, Alzheimer’s, ALS, and more. It is taking a translational medicine approach to finding targets and tracking progress with appropriate biomarkers. Between raising $350 million in venture capital and $250 million from its IPO, it’s off to an impressive start--at least financially speaking.
Of course, that’s not the only company getting off the ground. Read on for more financial news. -KT
Here’s a roundup of these stories and other top financial news from the past month.
- Ex-Genentech Employees’ Denali Breaks 2017 IPO Records, Raises $250M
- Cambridge’s Neon Therapeutics Completes $106M Crossover Series B Funding Round
- GW Pharmaceuticals Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276M
- Quanterix Corporation Announces Pricing of IPO
- Cambridge Biotech Obsidian Launches With $49.5M Investment From Google, Takeda, Vertex, Amgen and Others
Read More From Karl Thiel:
Did SAGE Therapeutics Just Break the CNS Curse?
